Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

By sjmartinez • November 3, 2023

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Epub ahead of print. PMID: 37918049.

Tags: Adverse events, Core outcome set, Harms, OMERACT, Publications, Rheumatology, rheumatology, safety

Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Mpox seroprevalence among sex workers and men who have sex with men preceding sustained urban outbreak in the Democratic Republic of the Congo

Mukadi PK, Merritt S, Nkuba-Ndaye A, Halbrook M, Anta Y, Bodisa Matamu T, Hasivirwe Vakaniaki E, Mukadi-Bamuleka D, Harrigan RJ, Lunyanga L, Kacita C, Kompany[...]

SARS-CoV-2 nucleocapsid induces hyperinflammation and vascular leakage through the Toll-like receptor signaling axis in macrophages

Yao Z, Alvarez PA, Chavez C, Delgado Y, Kaushal P, Buchholz DW, Austin D, Li Q, Yu Y, Zaiss AK, Arumugaswami V, Ding Q, Hsu[...]